Anticoagulation

03/03/2021
Category icon
Pharmacotherapy in Stable CAD: The ISCHEMIA Trial

Jonathan Yap, Derek P Chew, Gregg W Stone, et al

2020 APSC Consensus Recommendations on P2Y12 Inhibitor Use
Category icon
2020 APSC Consensus Recommendations on P2Y12 Inhibitor Use

Jack WC Tan, Derek P Chew, Muhamad Ali SK Abdul Kader, et al

Category icon
Redefining the Standard for Atrial Fibrillation: A Patient-centric Report

Carina Blomström-Lundqvist, Helmut Pürerfellner, Alex White, et al

Viscoelastic Haemostatic Assays in Cardiovascular Critical Care
Category icon
Viscoelastic Haemostatic Assays in Cardiovascular Critical Care

Aniket S Rali, Ahmed M Salem, Melat Gebre, et al

AF Symposium 2021 Summary: Pill-in-the-Pocket Anticoagulation for AF
Category icon
AF Symposium 2021 Summary: Pill-in-the-Pocket Anticoagulation for AF

Rod S Passman

TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy Versus Ticagrelor Plus Aspirin Beginning at 3 Months in High-risk Patients Undergoing Percutaneous Coronary Intervention
Category icon
Ticagrelor Monotherapy Versus Ticagrelor Plus Aspirin

Johny Nicolas, Usman Baber, Roxana Mehran,

Direct-acting Anticoagulants in Chronic Coronary Syndromes
Category icon
DOACs in Chronic Coronary Syndromes

Emmanuel Sorbets, Philippe Gabriel Steg,

Antithrombotic Therapy After Transcatheter Aortic Valve Implantation
Category icon
Antithrombotic Therapy After TAVI

Leslie Marisol Lugo, Rafael Romaguera, Joan Antoni Gómez-Hospital, et al

Summary of Current Guidelines Recommendations for Antithrombotic Therapy
Category icon
Dual Antiplatelet Therapy in CAD

Christopher N Floyd,

Antithrombotic Treatment After Coronary Intervention: Agreement and Controversy
Category icon
Antithrombotic Treatment After Coronary Intervention

Tamara García Camarero, José M de la Torre Hernández,

Between a Rock and a Hard Place: How to Use Antithrombotics in Patients Undergoing Transcatheter Aortic Valve Replacement
Category icon
Antithrombotics in TAVR

Mathew R Williams, Kelsey Grossman, Homam Ibrahim,

Personalised Approaches to Improving the Effect of Anti-platelet Agents: Where Do We Stand?
Category icon
Personalised Approaches to Improving the Effect of Anti-platelet Agents

Lucas C Godoy, Michael E Farkouh,

Videos

Play Icon
Christopher Porterfield , Felix Bourier , Andrea Di Cori et al
John Eikelboom, Ken Okumura, Jan Steffel et al
TN
Dominick J Angiolillo, Robert F Storey, Roxana Mehran et al
AF Symposium 2021 Summary: Pill-in-the-Pocket Anticoagulation for AF
Rod S Passman
Dr Steven Lubitz
Steven Lubitz
AHA 2020: The ALPHEUS Trial
Prof. Johanne Silvain
AHA 2020: Findings from the THALES trial — Prof Pierre Amarenco
Pierre Amarenco
Managing stroke risk in Patients Undergoing Catheter Ablation
Dhiraj Gupta, Hugh Calkins
Jan Steffel, Leonardo De Luca
TCT Connect 2020 Discussion: The VOYAGER PAD Study
Mirvat Alasnag, Connie N Hess
TCT Connect 2020: The XIENCE 90/28 Trials
Roxana Mehran
View From The Thoraxcenter: Wrap Up of TCT 2020
Nicolas M Van Mieghem, Joost Daemen
ESC Congress 2020 - NOACs Atrial Fibrillation
Jur ten Berg, Dominick J Angiolillo, Dhiraj Gupta et al
ESC Congress 2020 - Atrial fibrillation Patients in Focus
Gregory YH Lip, Elaine Hylek, Christian Ruff et al
Emerging Clinical Evidence on Left Atrial Appendage Closure
Ignacio Cruz, Jens Erik Nielsen-Kudsk, Prof Henning Ebelt
ESC 2020: Edoxaban for Elderly AF Patients — Dr Ken Okumura
Ken Okumura
ESC 2020: Downstream or upstream P2Y12 receptor blockers in NSTE-ACS
Giuseppe Tarantini
Kurt Huber, Davide Capodanno, Roxana Mehran et al
PCR e-Course 2020 Pharmacology & Coronary Interventions
Joost Daemen, Nicolas M Van Mieghem
Image
Hugh Calkins
PART 2: RE-DUAL PCI – Diabetes sub-group analysis
Christopher P Cannon
PART 1: RE-DUAL PCI – Switching Of NOACs
Jur ten Berg
Image
Jur ten Berg, Christopher P Cannon
Left Atrial Appendage Occlusion vs. Oral Anticoagulation Therapy with NOAC
Jens Erik Nielsen-Kudsk, A John Camm, Vivek Reddy
HRS 2020: Incidence of Silent Brain Infarcts in Anticoagulated Patients with AF
David Conen
PART 3: Practical implementation and current guidelines
Jan Steffel, Jur ten Berg, Stefan H Hohnloser
PART 2: Evolution of the data
Jan Steffel, Jur ten Berg, Stefan H Hohnloser
PART 1: Dual vs Triple Anti-thrombotic Therapy for Post-PCI Patients with Atrial Fibrillaiton
Jan Steffel, Jur ten Berg, Stefan H Hohnloser
Jan Steffel, Jur ten Berg, Stefan H Hohnloser
ACC 2020 Wrap Up: An Analysis of the Late-breaking Trials
Nicolas M Van Mieghem, Joost Daemen

Related Articles

Articles

Article icon
Pharmacotherapy in Stable CAD: The ISCHEMIA Trial

Jonathan Yap, Derek P Chew, Gregg W Stone,

Published:

Citation: European Cardiology Review 2021;16:e04.

DOI:

https://doi.org/10.15420/ecr.2020.48
2020 APSC Consensus Recommendations on P2Y12 Inhibitor Use

Jack WC Tan, Derek P Chew, Muhamad Ali SK Abdul Kader,

Published:

Citation: European Cardiology Review 2021;16:e02.

DOI:

https://doi.org/10.15420/ecr.2020.40
Redefining the Standard for Atrial Fibrillation: A Patient-centric Report

Carina Blomström-Lundqvist, Helmut Pürerfellner, Alex White,

Published:

Citation: European Cardiovascular Review 2021;16(Suppl 1):1–6.

DOI:

https://doi.org/10.15420/ecr.2021.16.s1
Viscoelastic Haemostatic Assays in Cardiovascular Critical Care

Aniket S Rali, Ahmed M Salem, Melat Gebre,

Published:

Citation: Cardiac Failure Review 2021;7:e01.

DOI:

https://doi.org/10.15420/cfr.2020.22